Zhu Junren, Ye Ping
Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Chin Med J (Engl). 2003 Jun;116(6):840-3.
To demonstrate the clinical efficacy of micronized fenofibrate on mildly-moderately elevated LDL-C levels and reduced HDL-C levels.
During 1998 - 1999, 2358 patients with type IIa, IIb and IV hyperlipidemia were monitored in 16 cities in China. They were treated daily with micronized fenofibrate (micronized lipanthyl) 200 mg for 8 weeks. Lipid levels before and after the treatment were measured and analyzed.
Micronized fenofibrate significantly increased HDL-C levels by 12.7%, the effect being inversely correlated to the baseline level of HDL-C. Out of the total patient population, a baseline level of HDL-C < 1.0 mmol/L was found in 837 patients: amongst this group, 510 patients (60.9%) were observed to have an increase in the level of HDL-C to > 1.0 mmol/L with a mean of 1.3 mmol/L, after 8-week micronized fenofibrate therapy. Furthermore, the mean LDL-C level decreased by 15.9% following an 8-week treatment of micronized fenofibrate, an effect positively correlated to the baseline level of LDL. In general, all patients tolerated the drug comfortably.
Short-term treatment of micronized fenofibrate in patients with dyslipidemia significantly increases HDL-C level and reduces mildly-moderately elevated LDL-C level. As expected, it also reduces triglyceride levels.
证明微粒化非诺贝特对轻度至中度升高的低密度脂蛋白胆固醇（LDL-C）水平及降低的高密度脂蛋白胆固醇（HDL-C）水平的临床疗效。
1998年至1999年期间，对中国16个城市的2358例IIa型、IIb型和IV型高脂血症患者进行监测。他们每日服用200毫克微粒化非诺贝特（微粒化力平之），持续8周。测量并分析治疗前后的血脂水平。
微粒化非诺贝特使HDL-C水平显著升高12.7%，该效果与HDL-C的基线水平呈负相关。在全部患者中，837例患者的HDL-C基线水平<1.0 mmol/L：在该组中，510例患者（60.9%）在接受8周微粒化非诺贝特治疗后，HDL-C水平升高至>1.0 mmol/L，平均为1.3 mmol/L。此外，接受8周微粒化非诺贝特治疗后，LDL-C平均水平下降了15.9%，该效果与LDL的基线水平呈正相关。总体而言，所有患者对该药物耐受性良好。
对血脂异常患者短期使用微粒化非诺贝特治疗可显著提高HDL-C水平，并降低轻度至中度升高的LDL-C水平。不出所料，它还能降低甘油三酯水平。
